Austria vs Netherlands: The number of people with susceptibility test result for rifampicin
Austria
86.84
in 2021
Netherlands
86.26
in 2021
Austria rank
80th
Netherlands rank
82nd
The number of people with susceptibility test result for rifampicin over time
- Austria
- Netherlands
How they compare
Austria currently reports 86.84 against 86.26 in Netherlands, a difference of 0.58.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Netherlands ahead.
Austria ranks 80th and Netherlands ranks 82nd of 146 countries.
Across the 2 decades both report, Austria averaged higher in 1 and Netherlands in 1.
Head to head by decade
| Decade | Austria | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 88.78 | 88.98 | 0.1968 | Netherlands |
| 2020s | 86.89 | 86.86 | 0.0298 | Austria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Austria or Netherlands?
- Austria, at 86.84 against 86.26 in Netherlands as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Austria and Netherlands?
- 0.58, with Austria ahead.
- How many years of comparable data are there for Austria and Netherlands?
- 5 years are reported by both, from 2017 to 2021.
- How do Austria and Netherlands rank globally for the number of people with susceptibility test result for rifampicin?
- Austria ranks 80th and Netherlands ranks 82nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.